Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Biogen Inc

2 Stocks You Could Keep in Your Portfolio Forever

Despite signs of inflation cooling in the United States, the IMF is not expecting the global economic picture to improve anytime soon. However, the cooling inflation might induce the Fed to ease the pace of rate hikes. As economic uncertainties remain, we think fundamentally solid stocks McDonald’s (MCD) and Biogen…

StockNews.com

The 4 Best Stocks to Buy This November

Favorable inflation data for October has raised the odds of slower federal rate hikes ahead. The market has been celebrating the inflation report, and experts believe the current rally could sustain for a while. Therefore, investors could buy quality stocks such as Gilead Sciences (GILD), Biogen (BIIB), Hillenbrand (HI), and…

StockNews.com

4 Stocks You Can Purchase at a Discount in Q4

Aggressive monetary policy tightening by the Fed and red-hot inflation have led to a broad stock market sell-off this year. However, the Fed is expected to slow the pace of rate hikes in the coming months. Therefore, it could be the right time to invest in fundamentally solid stocks Oracle…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

4 Nasdaq Stocks You'll Never Regret Buying

Amid the Fed's consecutive rate hikes, the Nasdaq composite has lost more than 30% year-to-date. However, it has gained marginally over the past month. Moreover, the Fed is expected to slow down the pace of rate hikes in the upcoming terms. Therefore, we think investors could consider buying quality Nasdaq…

StockNews.com

3 Strong Buy Stocks Begging to Be Bought in Q4

The Federal Reserve announced its fourth consecutive 75-bps rate hike yesterday. As the chances of the economy falling into a recession are tightening, fundamentally strong and resilient stocks Merck & Co (MRK), Biogen (BIIB), and Kroger (KR), which are rated Strong Buy in our proprietary rating system, could be safe…

StockNews.com

Despite fears of another major interest rate hike by the Fed in response to the stubborn inflation data for September, stocks such as Microsoft (MSFT) and Biogen (BIIB) have shown remarkable stability. Hence, it may be the right time to invest in them for market-beating returns. Keep reading.

StockNews.com

2 Top Biotech Stocks to Buy for the Long Haul and 1 to Sell

Government initiatives to expand domestic biotech production and research and rising private investments in advancing technologies are expected to boost the industry’s prospects. While we believe biotech stocks Vertex Pharmaceuticals (VRTX) and Biogen (BIIB) could be ideal investments for the long run, fundamentally weak Timber Pharmaceuticals (TMBR) might be best…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

2 Stocks with Great Track Records to Buy Right Now

Despite the Fed's aggressive interest rate hikes, the job market remains strong. However, given the mounting recessionary fears, it may be prudent to invest in UnitedHealth Group (UNH) and Biogen (BIIB), based on their solid fundamentals and impressive growth prospects. Continue Reading….

StockNews.com

3 Biotech Stocks to Buy for Q4 and 1 to Avoid

Favorable federal investments are anticipated to fuel further expansion in the biotech industry. Given the sector’s good prospects, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys. However, fundamentally weak stock Intra-Cellular Therapies (ITCI) might be best avoided. Read on….

StockNews.com

3 Biotech Stocks That'll Make You Richer and 1 That Won't

The biotech industry continues to stay resilient to broader economic challenges. Moreover, the planned multi-million-dollar government investments should bode well for the industry. Hence, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys to cash in on the industry’s prospects. However, fundamentally weak stock…

StockNews.com

What The Biogen Chart Reveals As Stock Rallies Hard On Alzheimer's Data

Going back to at least December 2014, Biogen Inc (NASDAQ: BIIB) has been diligently working on drugs to cure Alzheimer's disease. Both the negative and positive data revealed over the years have instigated wild price gyrations in the issue.

Benzinga

7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2022

Upgrades

Benzinga

Alzheimer’s progression slowed by drug in major trial

Eisai Co. and partner Biogen Inc. said their Alzheimer’s drug significantly slowed the disease, making it the first medicine to clearly blunt progression of the most common type of dementia in a definitive, large-scale trial.

Tribune News Service

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

4 Stocks You’ll Be Glad You Bought

The recent rally in the benchmark indices indicates improving investors’ sentiments. Moreover, analysts believe the economy could likely dodge a recession. So, it could be wise to consider buying quality stocks CVS Health (CVS), APA (APA), Biogen (BIIB), and Centene (CNC) now. Keep reading….

StockNews.com

5 Biotech Stocks in the Buy Zone This Week

The biotech industry is expected to see solid growth in the long term due to rising healthcare spending, breakthrough developments, and an aging population. Given the industry’s solid growth prospects and non-cyclical nature, it could be wise to invest in fundamentally strong biotech stocks Gilead Sciences (GILD), Biogen (BIIB), Jazz…

StockNews.com

5 Biotech Stocks to Buy and Hold for the Next Decade

The biotech industry seems poised to witness solid growth over the next decade with intensive innovation, breakthrough developments, and growing investments in the sector. So, given analysts’ promising growth outlook for the industry, it could be wise for investors to buy and hold fundamentally solid biotech stocks Vertex Pharmaceuticals (VRTX),…

Benzinga

Why Scholar Rock Shares Are Trading Higher Today

Scholar Rock Holding Corp (NASDAQ:SRRK) announced new data from the Phase 2 TOPAZ trial extension period evaluating apitegromab in non-ambulatory patients with Types 2 and 3 Spinal Muscular Atrophy (SMA) receiving an SMN therapy. The trial assessed patient outcomes after 24 months of treatment. All 35 non-ambulatory patients (Cohorts 2 and 3) and…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement

Biogen Inc. (NASDAQ:BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ:KPTI) that it has opted to terminate the companies' Asset Purchase Agreement dated January 24, 2018, as amended. As per the agreement, Karyopharm sold rights of its oral Selective Inhibitor of Nuclear Export compound KPT-350 and certain related assets to Biogen. KPTI received an upfront payment…

Benzinga

Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex

Catalyst Biosciences Inc (NASDAQ:CBIO) has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for $60 million. "This sale is part of the ongoing strategic process that we announced in February to explore alternatives and create value for shareholders. We have significantly reduced our cash burn and continue…

StockNews.com

3 Buy-Rated Biotechs to Buy in May

Despite logistical hurdles, the biotech industry is expected to expand solidly in the coming years on lucrative federal investments and strong demand. Therefore, we think it could be wise to bet on the stocks of quality biotech companies Biogen (BIIB), BioNTech (BNTX), and Incyte (INCY). These stocks are rated ‘Buy’…

Benzinga

Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug

Eisai Co Ltd (OTC:ESALY) has completed the rolling submission of the FDA marketing application under the accelerated approval for lecanemab (BAN2401) for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD. Eisai is collaborating with Biogen Inc (NASDAQ:BIIB) for drug development. Eisai has requested a Priority Review, while the lecanemab Phase 3…

Benzinga

Read Why Biogen Shares Are Trading Higher After Q1 Earnings

Biogen Inc (NASDAQ:BIIB) posted Q1 sales of 2.53 billion, beating the consensus of $2.49 billion, down 6% Y/Y. Multiple sclerosis (MS) revenue, including royalties on sales of Ocrevus, of $1.79 billion decreased by 3%. Spinraza's revenue of $441 million decreased 9% at actual currency and 6% at constant currency. Aduhelm's revenue was…

Benzinga

Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder

Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc (NASDAQ:BIIB) have initiated a rolling submission of a marketing application to the FDA for zuranolone in major depressive disorder (MDD). Zuranolone is an investigational two-week, once-daily oral drug developed for MDD and postpartum depression (PPD). The companies have submitted the nonclinical module and plan to submit the remaining…

Benzinga

Why This Analyst Believes Biogen Is 'Too Good to Ignore'

Biogen Inc’s (NASDAQ: BIIB) base business seems to be worth more than what the Street estimates, and it is possible that investors are not properly valuing royalty streams coming to the company, which contributes 15% of current revenues and 40% of the valuation, according to Wells Fargo.

1 2 3 4

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Microsoft Corporation

298 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.